Headlines about Oncomed Pharmaceuticals (NASDAQ:OMED) have been trending positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.1724305305396 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now (finance.yahoo.com)
- HC Wainwright Reaffirms Hold Rating for Oncomed Pharmaceuticals (OMED) (americanbankingnews.com)
- Oncomed Pharmaceuticals (OMED) Posts Earnings Results, Beats Expectations By $0.59 EPS (americanbankingnews.com)
- OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights (finance.yahoo.com)
- OncoMed tops Street 4Q forecasts (finance.yahoo.com)
Several brokerages recently issued reports on OMED. Cantor Fitzgerald set a $6.00 target price on Oncomed Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, January 4th. Zacks Investment Research raised Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Thursday, January 4th. Finally, HC Wainwright reissued a “hold” rating and set a $3.00 target price on shares of Oncomed Pharmaceuticals in a research note on Friday, March 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. Oncomed Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $5.31.
Oncomed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.59. The firm had revenue of $20.64 million during the quarter, compared to the consensus estimate of $5.10 million. equities analysts predict that Oncomed Pharmaceuticals will post -1.08 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/14/oncomed-pharmaceuticals-omed-receives-daily-coverage-optimism-score-of-0-26/2030269.html.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.